Final psychedelics guidance suggests FDA is receptive to helping companies succeed

The FDA has finalized its first formal guidance for studying psychedelic drugs in people, titled "Psychedelic Drugs:
Considerations for Clinical Investigations," issued on July 13, 2026, which sets the ground rules for research into psilocybin, LSD, and MDMA.

The final guidance reflects the agency's current thinking on psychedelic drug development, emphasizing the same evidentiary standards as other medicines while offering clarifications and compromises based on industry feedback.

The guidance covers clinical trial design, safety, manufacturing, and long-term follow-up, requiring double-blind designs at 12 weeks and follow-up for about a year to assess durability.

By finalizing this detailed guidance and engaging in public hearings, the FDA signals receptiveness to helping companies succeed in developing psychedelic therapies, balancing urgency with rigorous scientific standards.

This follows an April 2026 executive order and FDA fast-tracking of psychedelic-based therapies, indicating a supportive regulatory environment for companies in this space.